Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials
Dermatology Online Journal · 09.05.2026 · 32 (2)
DOI: 10.25251/t1b8ft53 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Creighton Pfau und 3 weiteren Autor:innen. Beteiligte Einrichtung: AT Still University School of Osteopathic Medicine in Arizona, Mesa, AZ, USA. Hauptthemen laut MEDLINE: Dermatologic Agents, Interleukin-17, Interleukin-23, Psoriasis. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Biologic therapies targeting interleukin-17 (IL-17) and interleukin-23 (IL-23) pathways have transformed psoriasis management, with IL-17 inhibitors widely regarded as achieving faster clearance. However, the clinical significance of differences in clearance times remains unclear.
Objective
To compare time to achieve a 75% reduction in the Psoriasis Area and Severity Index (PASI75) between IL-17 and IL-23 inhibitors using data from head-to-head clinical trials.
Methods
A PubMed search identified trials reporting PASI75 response times for IL-17 and IL-23 inhibitors. Graphs from 12 studies were analyzed using Engauge Digitizer Software to estimate the time until half of participants reached PASI75.
Results
IL-17 inhibitors achieved PASI75 faster than IL-23 inhibitors, with average response times of 4.5 weeks versus 7 weeks, respectively. The fastest IL-17 agent (bimekizumab) reached PASI75 in 2.5 weeks, while the fastest IL-23 agent (risankizumab) required 5.5 weeks. Differences between classes were smaller than anticipated, particularly for newer IL-23 inhibitors targeting the p19 subunit.
Limitations
PASI75 timepoints were estimated from published graphs, introducing potential measurement error.
Conclusion
IL-17 inhibitors generally achieve faster psoriasis clearance than IL-23 inhibitors, but the clinical relevance of this difference is limited. Safety and long-term efficacy profiles should guide treatment selection, highlighting the importance of personalized patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AT Still University School of Osteopathic Medicine in Arizona, Mesa, AZ, USA.
- Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Zitieren
APA
Pfau, C., Lovell, K. K., Ozbeki, H., & Feldman, S. R. (2026). Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials. Dermatology Online Journal, 32(2). https://doi.org/10.25251/t1b8ft53
Vancouver
Pfau C, Lovell KK, Ozbeki H, Feldman SR. Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials. Dermatology Online Journal. 2026;32(2). doi:10.25251/t1b8ft53
BibTeX
@article{Pfau2026,
author = {Pfau, Creighton and Lovell, Katie K and Ozbeki, Hanna and Feldman, Steven R},
title = {Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {2},
doi = {10.25251/t1b8ft53}
}
EUVIMED